Completed PHASE2 INTERVENTIONAL 4-arm NCT01030432

Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotypes 1 and 4 Chronic Hepatitis C Infection

Sponsor: Bristol-Myers Squibb

Conditions Hepatitis C Virus

Interventions BMS-650032 Peginterferon Alfa-2a Placebo Ribavirin

Updated 8 times since 2017 Last updated: Sep 23, 2015 Started: Feb 28, 2010 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hepatitis C Virus, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 8 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Baltimore, United States , Barcelona, Spain , Birmingham, United States , Buenos Aires, Argentina , Chapel Hill, United States , Ciudad de Buenos Aires, Argentina , Créteil, France , Dublin, Ireland , Fairfax, United States and 27 more locations